{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["EGFR TKIs", "MD simulations", "anticancer", "docking", "thieno[2,3-d]pyrimidine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37529910", "DateCompleted": {"Year": "2023", "Month": "10", "Day": "23"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "08", "Day": "02"}], "Language": ["eng"], "ELocationID": ["10.4155/fmc-2023-0086"], "Journal": {"ISSN": "1756-8927", "JournalIssue": {"Volume": "15", "Issue": "13", "PubDate": {"Year": "2023", "Month": "Jul"}}, "Title": "Future medicinal chemistry", "ISOAbbreviation": "Future Med Chem"}, "ArticleTitle": "Discovery of new thieno[2,3-<i>d</i>]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment.", "Pagination": {"StartPage": "1167", "EndPage": "1184", "MedlinePgn": "1167-1184"}, "Abstract": {"AbstractText": ["<b>Background:</b> EGFR has been considered a vital molecular target in cancer management. <b>Aim:</b> The discovery of new thieno[2,3-<i>d</i>]pyrimidine derivatives as EGFR tyrosine kinase inhibitors. <b>Methods:</b> Nine derivatives were designed, synthesized and subjected to <i>in vitro</i> and <i>in silico</i> studies. <b>Results:</b> Compound <b>7a</b> significantly inhibited the growth of HepG2 and PC3 cells for both EGFR wild-type and EGFR<sub>T790M</sub>. Compound <b>7a</b> caused a significant apoptotic effect, arresting HepG2 cells' growth in the S and G2/M phases. Docking and molecular dynamics simulation studies confirmed the correct and stable binding modes of the synthesized compounds against the active sites. <b>Conclusion:</b> Compound <b>7a</b> is a promising dual EGFR inhibitor for cancer treatment."]}, "AuthorList": [{"Identifier": ["0000-0002-9649-0985"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt."}], "LastName": "Sobh", "ForeName": "Eman A", "Initials": "EA"}, {"Identifier": ["0000-0002-2016-0728"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt."}], "LastName": "Dahab", "ForeName": "Mohammed A", "Initials": "MA"}, {"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-4497-5013"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, PO Box 84428, Riyadh, 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": ["0000-0001-7875-7538"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo, 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy & Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering & Biotechnology Research Institute, City of Scientific Research & Technological Applications (SRTA-City), Alexandria, 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Future Med Chem", "NlmUniqueID": "101511162", "ISSNLinking": "1756-8919"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tyrosine Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Tyrosine Kinase Inhibitors"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Pyrimidines"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["pharmacology", "therapeutic use", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2023", "Month": "10", "Day": "23", "Hour": "12", "Minute": "44"}, {"Year": "2023", "Month": "8", "Day": "2", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "8", "Day": "2", "Hour": "5", "Minute": "27"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37529910", "10.4155/fmc-2023-0086"]}}], "PubmedBookArticle": []}